Edit |   |
---|---|
Antigenic Specificity | CD28 (Theralizumab biosimilar) |
Clone | monoclonal |
Host Species | n/a |
Reactive Species | human |
Isotype | IgG4 |
Format | Protein A/G purified, low endotoxin |
Size | 50mg |
Concentration | 5mg/ml |
Applications | Functional Assays. RUO |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Specificity: detects human CD28. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Theralizumab. Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family). It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006. |
Immunogen | n/a |
Other Names | TGN1412, CD28-SuperMAB, TAB08 |
Gene, Accession # | UniProt: P10747 |
Catalog # | ICH5023-50mg |
Price | $3750 |
Order / More Info | CD28 (Theralizumab biosimilar) Antibody from ICHORBIO |
Product Specific References | n/a |
U.S. OFFICE
987 Old Eagle School Rd, Ste 709
Wayne, PA 19087
us@ichor.bio